The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
The FTC’s investigation into PBM practices began in 2022. Last summer, the agency released a scathing interim report on the industry. It detailed how increasing concentration enabled the three ...
Dealbreaker on MSN13d
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug PricesThe pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...
2don MSNOpinion
As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback